The PE ratio for Ani Pharmaceuticals stock stands at 50.92 as of Oct 22, 2024. This results from the current EPS of $1.18 and stock price of $60.08. A decrease of 25% has been seen in the P/E ratio compared to the average of 67.6 of the last 4 quarters.
Over the last ten years, the average PE ratio of Ani Pharmaceuticals has been 433.97. The current 50.92 PE ratio is 88% below the historical average. Over the past ten years, ANIP's PE ratio was at its highest in the Jun 2018 quarter at 6,680, with a price of $66.8 and an EPS of $0.01. The Sep 2015 quarter recorded the bottom point at 13.21, with a price of $39.51 and an EPS of $2.99.
Maximum annual increase: 429.36% in 2016
Year | PE ratio | Change |
---|---|---|
2023 | 64.12 | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | 120.92 | 251.82% |
2018 | 34.37 | N/A |
2017 | N/A | N/A |
2016 | 178.29 | 429.36% |
2015 | 33.68 | 55.85% |
2014 | 21.61 | N/A |
Currently, ANIP's PE ratio is below the 5 and 10-year averages.
ANIP's PE ratio is higher than its peer stocks NVS and CAH. Ani Pharmaceuticals's current PE ratio of 50.92 is above the average of its peers, which is 20.72.
Stock name | PE ratio | Market cap |
---|---|---|
NVS Novartis AG | 14.44 | $232.75B |
JAZZ Jazz Pharmaceuticals plc | 17.69 | $6.86B |
RPRX Royalty Pharma plc | 18.12 | $16.24B |
CAH Cardinal Health Inc | 32.16 | $27.29B |
ANIP Ani Pharmaceuticals Inc | 50.11 | $1.24B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $20.86B |
CLDX Celldex Therapeutics Inc | N/A | $1.9B |
PFE Pfizer Inc | N/A | $163.54B |
ANIP's price to earnings ratio is 50.92 as of Oct 22, 2024.
The 5-year average PE ratio for ANIP stock is 78.25.
Over the last ten years, the quarterly PE ratio reached a historic high of 6,680 in the Jun 2018 quarter.
ANIP's price to earnings ratio is currently 88% below its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Oct 22, 2024), Ani Pharmaceuticals's stock price is $60.08. The earnings per share for the trailing twelve months (TTM) ending Jun 2024 is $1.18. Therefore, Ani Pharmaceuticals's P/E ratio for today is 50.92. PE RATIO(50.92) = STOCK PRICE($60.08) / TTM EPS($1.18)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.